Neurotech International Ltd has released a press release.
Disclosure Document
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurotech International Ltd. on 6ix
Earlier from Neurotech International
- Commencement of Phase II/III ASD Clinical Trial
- NTI Receives HREC/TGA Approval for Phase II/III ASD Trial
- Neurotech Receives $1.2M R&D Tax Rebate
- Reinstatement to Quotation
- Neurotech Completes $9.0M Placement
Later from Neurotech International
- NTI Granted FDA Pre-IND Meeting for NTI164 in ASD
- HREC Approval for Phase I/II PANDAS/PANS Clinical Trial
- Approval for Additional Phase I/II ASD Trial Extension
- First Patient Treated in Phase I/II PANDAS/PANS Trial
- Phase I/II ASD Clinical Trials Results at 52 Weeks
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International